PSP Research’s Apogee Therapeutics APGE Stock Holding History

PSP Research’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,500	Closed	-$210K	–	77
2026 Q1	$210K	Sell	2,500 -4,484	-64%	-$326K	0.15%	70
2025 Q4	$527K	Buy	+6,984	New	+$440K	0.46%	52

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

PSP Research's APGE Position: Q2 2026 in Review

PSP Research sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 2,500 shares — an estimated $210K sold.

PSP Research first reported a position in APGE in Q4 2025 and held it in 2 quarters. The position peaked at $527K in Q4 2025. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

PSP Research reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
PSP Research sold 2,500 Apogee Therapeutics shares in Q2 2026, an estimated $210K.
PSP Research first reported a position in Apogee Therapeutics in Q4 2025 and held it in 2 quarters.
PSP Research's Apogee Therapeutics position peaked at $527K in Q4 2025.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.